Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies

  1. Kathleen G. Beavis
  2. Scott M. Matushek
  3. Ana Precy F. Abeleda
  4. Cindy Bethel
  5. Carlissa Hunt
  6. Stephanie Gillen
  7. Angelica Moran
  8. Vera Tesic

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.jcv.2020.104468
  2. ScreenIT

    SciScore for 10.1101/2020.05.11.089862: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    The EUROIMMUN Anti-SARS-CoV-2 assay is an enzyme-linked immunosorbent assay (ELISA) that provides semi-quantitative in vitro determination of human antibodies of immunoglobulin classes IgA and IgG against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in serum or EDTA plasma (6-7).
    IgG against severe acute respiratory syndrome coronavirus 2
    suggested: None
    To detect the bound antibodies, a second incubation is carried out using an enzyme-labelled antihuman IgA or IgG (enzyme conjugate) catalyzing a color reaction.
    an enzyme-labelled antihuman IgA
    suggested: None
    IgG (enzyme conjugate) catalyzing a color
    suggested: None
    Software and Algorithms
    SentencesResources
    All statistical analyses were performed using GraphPad Prism version 8.4.1.
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
    • No funding statement was detected.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.05.11.089862v1 on bioRxiv